LPTX News and Press, Leap Therapeutics Inc. From 09/27/22

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science o...

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology...

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors PR Newswire CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targ...

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress PR Newswire Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with ...

Leap Therapeutics press release ( NASDAQ: LPTX ): Q2 GAAP EPS of -$0.15 misses by $0.05 . Cash and cash equivalents totaled $90.9 million at June 30, 2022, expected to provide financial runway to mid-2024 Shares +1.54% PM. For further details see: Lea...

Leap Therapeutics Reports Second Quarter 2022 Financial Results PR Newswire CAMBRIDGE, Mass. , Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, t...

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute PR Newswire Dr. Bertagnolli to Transition Off Leap's Board of Directors CAMBRIDGE, Mass. , Aug. 12, 2022 /PRNewswire/ --...

Leap Therapeutics ( NASDAQ: LPTX ) said part C of an ongoing phase 2 trial of its medicine DKN-01, in combination with BeiGene ( NASDAQ: BGNE ) and Novartis' ( NVS ) tislelizumab, has begun in patients with gastric or gastroesophageal junction ca...

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer PR Newswire Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with Bei...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...